About this Research Topic
Alzheimer’s disease (AD) is the most devastating chronic neurodegenerative disorder and the primary cause of dementia that is becoming a global threat. By 2040, 81.1 million people worldwide will be affected by this disease, experts suggest that the number of dementia patients will be doubled every 20 years and will affect social, economic, and health problems significantly in the near future. The two main hallmarks of AD are the extracellular deposition of senile plaques (composed of amyloid beta proteins) and the intraneuronal tangles formed with hyperphosphorylated tau units. Historically, scientists thought that eliminating plaques and tangles will stop neuroinflammation but later it was established that neuroinflammation precedes the appearance of tangles and plaques and leads to severe neuronal death and synaptic dysfunction. Currently, there are no approved drugs to treat neuroinflammation.
Neuroinflammation is commonly characterized as a central nervous system (CNS) response to brain injury, infection, and progression of neurodegenerative diseases. This inflammatory response is aided by the production of cytokines, chemokines, reactive oxygen species (ROS), and various other cellular responses. Understanding this complex process is crucial to identify valid targets and developing therapeutics against them. Research has been ongoing for decades to slow down or combat neuroinflammation in Alzheimer’s Disease progression, which includes small molecules, peptides, nano formulation, antibody treatment, and many more. Currently, there are no approved drugs to combat neuroinflammation although several biomarkers and small molecules are in clinical trials, and several are failed in clinical trials as well. Therefore, alternative methods, innovative designs, the development of therapeutic strategies, and modifications of previously designed chemical compounds are highly needed to slow down the disease progression.
This research topic accumulates all ongoing and future research on chemical approaches combating neuroinflammation. We invite authors to submit Original Research Articles, Brief Research descriptions, Clinical Approaches, Chemical and Pharmacophore based analysis, Review articles with in-depth analysis of new chemical molecules to combat neuroinflammation, alongside, future direction toward different pharmacological targets, modification of advanced biomarkers in regular and clinical trials, including but not limited to:
•Receptor-based or Structure-based designing of chemical molecules against Neuroinflammation
•Structure Activity Relationship (SAR) based optimization of anti-inflammatory molecules
•Identification of neuroinflammatory changes involving the expression of different proteins and the development of inhibitors
•Pharmacophore analysis and identification targets to change neuroinflammation
•Identify novel biomarkers or mechanistic role of biomarkers in neuroinflammatory changes
•Validation, and comparison of novel biomarkers with existing biomarkers
•Cutting-edge research (e.g., genome sequencing, CRISPER/Cas9 etc.) based approaches for the regulation of Neuroinflammation
•Epigenetic research study involving neuroinflammatory changes
•Clinical/longitudinal research studies for the optimization of drugs to combat neuroinflammation in AD.
Topic Editor Dr. Dwaipayan Sen is employed by Astellas Gene Therapies. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Neuroinflammation is commonly characterized as a central nervous system (CNS) response to brain injury, infection, and progression of neurodegenerative diseases. This inflammatory response is aided by the production of cytokines, chemokines, reactive oxygen species (ROS), and various other cellular responses. Understanding this complex process is crucial to identify valid targets and developing therapeutics against them. Research has been ongoing for decades to slow down or combat neuroinflammation in Alzheimer’s Disease progression, which includes small molecules, peptides, nano formulation, antibody treatment, and many more. Currently, there are no approved drugs to combat neuroinflammation although several biomarkers and small molecules are in clinical trials, and several are failed in clinical trials as well. Therefore, alternative methods, innovative designs, the development of therapeutic strategies, and modifications of previously designed chemical compounds are highly needed to slow down the disease progression.
This research topic accumulates all ongoing and future research on chemical approaches combating neuroinflammation. We invite authors to submit Original Research Articles, Brief Research descriptions, Clinical Approaches, Chemical and Pharmacophore based analysis, Review articles with in-depth analysis of new chemical molecules to combat neuroinflammation, alongside, future direction toward different pharmacological targets, modification of advanced biomarkers in regular and clinical trials, including but not limited to:
•Receptor-based or Structure-based designing of chemical molecules against Neuroinflammation
•Structure Activity Relationship (SAR) based optimization of anti-inflammatory molecules
•Identification of neuroinflammatory changes involving the expression of different proteins and the development of inhibitors
•Pharmacophore analysis and identification targets to change neuroinflammation
•Identify novel biomarkers or mechanistic role of biomarkers in neuroinflammatory changes
•Validation, and comparison of novel biomarkers with existing biomarkers
•Cutting-edge research (e.g., genome sequencing, CRISPER/Cas9 etc.) based approaches for the regulation of Neuroinflammation
•Epigenetic research study involving neuroinflammatory changes
•Clinical/longitudinal research studies for the optimization of drugs to combat neuroinflammation in AD.
Topic Editor Dr. Dwaipayan Sen is employed by Astellas Gene Therapies. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Keywords: Alzheimer's disease, chronic neurodegenerative disorder, dementia, senile plaques, tau units, neuroinflammation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
